Sign in to view content

Two-Year Results From the Subretinal RGX-314 Gene Therapy Phase 1/2a Study for the Treatment of Neovascular AMD

Robert L. Avery, MD

Video
Published 2021

Related

Episode 15: Serum VEGF Levels in the IVAN Trial with Dr. Usha Chakravarthy
Keyvan Koushan, MD, FRCSC
Member Podcasts
2018
Prophylactic Ranibizumab for Exudative AMD in Vulnerable Eyes With Nonexudative AMD Trial (PREVENT) A Prospective Controlled Clinical Trial
Maziar Lalezary, MD
Annual Meeting Talks
2018
Abicipar Phase 2 MAPLE Trial Supports Improved Safety for Patients with nAMD Following a Modified Manufacturing Process
Raj K. Maturi, MD
Updates from the Field
2019

Category: AMD-Neovascular

See more